林业发展局任命Richard Pazdur博士在机构动荡中领导药物安全和批准工作。 FDA appoints Dr. Richard Pazdur to lead drug safety and approval amid agency turmoil.

美国食品和药物管理局任命26年经验丰富的FDA资深医生,前瘤中心主任理查德·帕兹杜尔博士, 成为药物评估与研究中心的新主任, The FDA has named Dr. Richard Pazdur, a 26-year FDA veteran and former head of the Oncology Center of Excellence, as the new director of the Center for Drug Evaluation and Research, succeeding Dr. George Tidmarsh, who resigned after an ethics review and allegations of misconduct. 在工作人员离开1 000多名、士气低落和内部冲突的不稳定时期,Pazdur将领导该机构最大的单位,负责毒品安全和批准工作。 Pazdur will lead the agency’s largest unit, responsible for drug safety and approval, amid a period of instability marked by over 1,000 staff departures, low morale, and internal conflicts. 他将监督新的举措,包括一个在一至两个月内批准国家关键药物的快车道方案,比前六个月的最低数量大幅下降。 He will oversee new initiatives, including a fast-track program to approve nationally critical drugs in one to two months, a significant reduction from the previous six-month minimum.